CASI Pharms

CASI NASDAQ
3.200
0.000
0.00%
Opening 12:48 06/19 EDT
Open
3.220
Prev Close
3.200
High
3.260
Low
3.190
Volume
26.97K
Avg Vol (3M)
166.27K
52 Week High
8.89
52 Week Low
2.730
% Turnover
0.03%
Market Cap
254.85M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers CASI Pharms CASI stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).
MORE >

Recently

Name
Price
%Change